Oncogenic PI3K mutations in 50% of human cancers, PTEN status as the second most-often mutated tumor suppressor gene in human cancers, and multiple efforts to therapeutically inhibit PI3K signaling for cancer, metabolic, and immune diseases further illustrate the broad therapeutic importance of preventing PIP3 hyperactivity (10, 11). Here, PIK3CD is linked to cancer.